# A Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes Mellitus

Study · id `cardio:ct-nct06140485` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06140485](<https://clinicaltrials.gov/study/NCT06140485>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06140485

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT06140485. Randomized; triple masking; primary purpose treatment. Start 2024-03 (anticipated); primary completion 2025-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT06140485, source copy `cardio:ctgov-nct06140485-2023-11-22`, retrieved 2026-10-26)
- Planned start: 2024-03 (anticipated) (ClinicalTrials.gov record NCT06140485, source copy `cardio:ctgov-nct06140485-2023-11-22`, retrieved 2026-10-26)
- Primary completion: 2025-09 (anticipated) (ClinicalTrials.gov record NCT06140485, source copy `cardio:ctgov-nct06140485-2023-11-22`, retrieved 2026-10-26)
- Completion: 2025-10 (anticipated) (ClinicalTrials.gov record NCT06140485, source copy `cardio:ctgov-nct06140485-2023-11-22`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06140485-2023-11-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Dietary supplement): NW Low-Glu®
- Intervention (Drug): Metformin
- Lead sponsor: Natural Wellness Egypt
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: df3ff65354ca56314ec4358ec35910ad37b5ee397ecd858347cac516484f6e92
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
